Sarah Cavanaugh
Senior Vice President
Corporate Affairs and Administration
Here you will find a summary of Celldex Therapeutics, Inc.'s latest financial information.
| Market Capitalization (Mil) $ | 67.38 |
| Shares Outstanding (Mil) | 11.50 |
| Shares Outstanding, Average (FY) (Mil) | 8.57 |
| Float (Mil) | 11.45 |
Copyright Morningstar
FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
About
Investors & Media
© 2019 Celldex Therapeutics, All rights reserved | Site Map | Privacy Policy | Terms of Use | Contact
